Mueller, Susanne G.
https://orcid.org/0000-0002-5515-4432
Mayo Clinic
San Francisco VA Medical Center
Citations 2
Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2
Jack, Clifford R. , Barnes, Josephine , Bernstein, Matt A. , Borowski, Bret, Brewer, James, Clegg, Shona , Dale, Anders M. , Carmichael, Owen , Ching, Christopher R. K. , DeCarli, Charles , Desikan, Rahul S. , Fennema‐Notestine, Christine , Fjell, Anders M. , Fox, Nick C. , Gunter, Jeff, Holland, Dominic , Hua, Xue , Kantarci, Kejal , Krueger, Gunnar, Leung, Kelvin K., Mackin, Scott, Maillard, Pauline , Malone, Ian B. , Mattsson, Niklas , McEvoy, Linda K. , Modat, Marc , Mueller, Susanne G. , Nosheny, Rachel L. , Ourselin, Sébastien , Schuff, Norbert, Senjem, Matthew L. , Simonson, Alix, Thompson, Paul M. , Rettmann, Dan , Vemuri, Prashanthi , Walhovd, Kristine B. , Zhao, Yansong , Zuk, Samantha M., Weiner, Michael W. , DeCarli, Charles , Borowski, Bret J, Zuk, Samantha, Fletcher, Evan M. , Gutman, Boris A , Insel, Philip S. , Killiany, Ronald , Bernstein, Matt A , Jack, Clifford R , Vemuri, Prashanthi , Dale, Anders M , Thompson, Paul M , Senjem, Matthew L , Ching, Christopher R K , Kantarci, Kejal , Fox, Nick C , Maillard, Pauline
Alzheimer's & Dementia | July 17, 2015 | Volume: 11 | Issue: 7 | Pages: 740-756
AbstractIntroductionAlzheimer's Disease Neuroimaging Initiative (ADNI) is now in its 10th year. The primary objective of the magnetic resonance imaging (MRI) core of ADNI has been to improve methods for clinical trials in Alzheimer's disease (AD) and related disorders.MethodsWe review the contributions of the MRI core from present and past cycles of ADNI (ADNI‐1, ‐Grand Opportunity and ‐2). We also review plans for the future‐ADNI‐3.ResultsContributions of the MRI core include creating standardized acquisition protocols and quality control methods; examining the effect of technical features of image acquisition and analysis on outcome metrics; deriving sample size estimates for future trials based on those outcomes; and piloting the potential utility of MR perfusion, diffusion, and functional connectivity measures in multicenter clinical trials.DiscussionOver the past decade the MRI core of ADNI has fulfilled its mandate of improving methods for clinical trials in AD and will continue to do so in the future.
Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI)
Mueller, Susanne G. , Weiner, Michael W. , Thal, Leon J., Petersen, Ronald C. , Jagust, William J. , Trojanowski, John Q. , Toga, Arthur W. , Beckett, Laurel , Jack, Clifford R. , Toga, Arthur W
Alzheimer's & Dementia | August 25, 2005 | Volume: 1 | Issue: 1 | Pages: 55-66
Abstract With the increasing life expectancy in developed countries, the incidence of Alzheimer's disease (AD) and thus its socioeconomic impact are growing. Increasing knowledge over the last years about the pathomechanisms involved in AD allow for the development of specific treatment strategies aimed at slowing down or even preventing neuronal death in AD. However, this requires also that (1) AD can be diagnosed with high accuracy, because non‐AD dementias would not benefit from an AD‐specific treatment; (2) AD can be diagnosed in very early stages when any intervention would be most effective; and (3) treatment efficacy can be reliably and meaningfully monitored. Although there currently is no ideal biomarker that would fulfill all these requirements, there is increasing evidence that a combination of currently existing neuroimaging and cerebrospinal fluid (CSF) and blood biomarkers can provide important complementary information and thus contribute to a more accurate and earlier diagnosis of AD. The Alzheimer's Disease Neuroimaging Initiative (ADNI) is exploring which combinations of these biomarkers are the most powerful for diagnosis of AD and monitoring of treatment effects.